Shandong Sito Bio-technology Co., Ltd. (SHE:300583)
China · Delayed Price · Currency is CNY 14.88
+0.26 (1.78%)
Jan 23, 2026, 3:04 PM CST
SHE:300583 Revenue
Shandong Sito Bio-technology had revenue of 241.43M CNY in the quarter ending September 30, 2025, with 21.70% growth. This brings the company's revenue in the last twelve months to 954.76M, down -14.87% year-over-year. In the year 2024, Shandong Sito Bio-technology had annual revenue of 970.60M, down -24.16%.
Revenue (ttm)
954.76M
Revenue Growth
-14.87%
P/S Ratio
2.96
Revenue / Employee
995.57K
Employees
959
Market Cap
2.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 970.60M | -309.18M | -24.16% |
| Dec 31, 2023 | 1.28B | -32.33M | -2.46% |
| Jan 1, 2023 | 1.31B | 109.49M | 9.10% |
| Jan 1, 2022 | 1.20B | 289.44M | 31.70% |
| Dec 31, 2020 | 913.19M | -52.61M | -5.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Jiangsu Sihuan Bioengineering | 341.90M |
| Sailong Pharmaceutical Group | 244.84M |
| Shanghai Serum Bio-Technology | 196.76M |